ID   OVCAR-4
AC   CVCL_1627
SY   OVCAR 4; NIH:OVCAR-4; NIH:OVCAR4; OVCAR.4; OVCAR4; Ovcar4
DR   BTO; BTO:0002561
DR   CLO; CLO_0037096
DR   EFO; EFO_0005442
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03472889
DR   BioSample; SAMN10987768
DR   cancercelllines; CVCL_1627
DR   Cell_Model_Passport; SIDM00092
DR   ChEMBL-Cells; CHEMBL3307517
DR   ChEMBL-Targets; CHEMBL614051
DR   Cosmic; 688105
DR   Cosmic; 875860
DR   Cosmic; 897434
DR   Cosmic; 905990
DR   Cosmic; 974295
DR   Cosmic; 1044240
DR   Cosmic; 1092624
DR   Cosmic; 1175884
DR   Cosmic; 1305313
DR   Cosmic; 1312355
DR   Cosmic; 1436034
DR   Cosmic; 1998466
DR   Cosmic-CLP; 905990
DR   DepMap; ACH-000617
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 905990
DR   GEO; GSM2174
DR   GEO; GSM50220
DR   GEO; GSM50284
DR   GEO; GSM185137
DR   GEO; GSM185138
DR   GEO; GSM186442
DR   GEO; GSM186443
DR   GEO; GSM743475
DR   GEO; GSM743494
DR   GEO; GSM750829
DR   GEO; GSM784572
DR   GEO; GSM799364
DR   GEO; GSM799427
DR   GEO; GSM847107
DR   GEO; GSM844669
DR   GEO; GSM844670
DR   GEO; GSM851935
DR   GEO; GSM887484
DR   GEO; GSM888565
DR   GEO; GSM1153436
DR   GEO; GSM1181279
DR   GEO; GSM1181286
DR   GEO; GSM1374801
DR   GEO; GSM1670318
DR   GEO; GSM2124646
DR   IARC_TP53; 21085
DR   IARC_TP53; 21126
DR   IARC_TP53; 30217
DR   LiGeA; CCLE_876
DR   LINCS_LDP; LCL-1697
DR   Millipore; SCC258
DR   NCI-DTP; OVCAR-4
DR   PharmacoDB; OVCAR4_1218_2019
DR   PRIDE; PXD005942
DR   PRIDE; PXD005946
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1627
DR   PubChem_Cell_line; CVCL_1627
DR   SKY/M-FISH/CGH; 2817
DR   Wikidata; Q54937010
RX   PubMed=1348364;
RX   PubMed=2041050;
RX   PubMed=2307530;
RX   PubMed=3335022;
RX   PubMed=3930572;
RX   PubMed=6372095;
RX   PubMed=6385258;
RX   PubMed=7718330;
RX   PubMed=9041185;
RX   PubMed=10700174;
RX   PubMed=12080474;
RX   PubMed=12960427;
RX   PubMed=15748285;
RX   PubMed=17088437;
RX   PubMed=19372543;
RX   PubMed=20164919;
RX   PubMed=22068913;
RX   PubMed=22336246;
RX   PubMed=22347499;
RX   PubMed=22384151;
RX   PubMed=22460905;
RX   PubMed=22628656;
RX   PubMed=23839242;
RX   PubMed=23856246;
RX   PubMed=23933261;
RX   PubMed=24023729;
RX   PubMed=24279929;
RX   PubMed=24670534;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25984343;
RX   PubMed=26589293;
RX   PubMed=27235858;
RX   PubMed=27377824;
RX   PubMed=27397505;
RX   PubMed=27807467;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=32612269;
RX   PubMed=35839778;
WW   https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
WW   https://strap.nci.nih.gov/celline_detail.php?sample_id=23
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: JFCR39 cancer cell line panel.
CC   Part of: KuDOS 95 cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: NCI-60 cancer cell line panel.
CC   Population: Caucasian.
CC   Doubling time: 34 hours (PubMed=7718330); 43 hours (PubMed=25984343); 41.4 hours (NCI-DTP=OVCAR-4).
CC   HLA typing: A*01:01:01,32:01; B*08:01,40:02; C*07,15; DPB1*04:01,13:01; DQB1*02:01,03:01:01; DRB1*03:01:01,04:01:01 (PubMed=15748285).
CC   HLA typing: A*01:01,32:03; B*08:01,40:02; C*07:01,15:02 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu130Val (c.388C>G); ClinVar=VCV000458543; Zygosity=Homozygous (PubMed=17088437; PubMed=24023729).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Fluorescence phenotype profiling.
CC   Omics: lncRNA expression profiling.
CC   Omics: Metabolome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=3.58%; East Asian, South=0%; South Asian=0%; European, North=53.46%; European, South=42.96% (PubMed=30894373).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): Cosmic-CLP; Genomics_Center_BCF_Technion; Millipore; PubMed=19372543; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D10S1248: 13,15
ST   D12S391: 23
ST   D13S317: 9
ST   D16S539: 11
ST   D18S51: 15
ST   D19S433: 13,15
ST   D1S1656: 15
ST   D21S11: 28,31
ST   D22S1045: 11,15
ST   D2S1338: 23
ST   D2S441: 10,15
ST   D3S1358: 15
ST   D5S818: 13
ST   D7S820: 10,11
ST   D8S1179: 13
ST   FGA: 21
ST   Penta D: 12,14
ST   Penta E: 11
ST   TH01: 9
ST   TPOX: 8
ST   vWA: 14,18
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   42Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 42
//
RX   PubMed=1348364; DOI=10.1073/pnas.89.7.3070;
RA   Godwin A.K., Meister A., O'Dwyer P.J., Huang C.-S., Hamilton T.C.,
RA   Anderson M.E.;
RT   "High resistance to cisplatin in human ovarian cancer cell lines is
RT   associated with marked increase of glutathione synthesis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:3070-3074(1992).
//
RX   PubMed=2041050; DOI=10.1093/jnci/83.11.757;
RA   Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D.,
RA   Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A.,
RA   Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.;
RT   "Feasibility of a high-flux anticancer drug screen using a diverse
RT   panel of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 83:757-766(1991).
//
RX   PubMed=2307530; DOI=10.1002/ijc.2910450306;
RA   Schilder R.J., Hall L., Monks A., Handel L.M., Fornace A.J. Jr.,
RA   Ozols R.F., Fojo A.T., Hamilton T.C.;
RT   "Metallothionein gene expression and resistance to cisplatin in human
RT   ovarian cancer.";
RL   Int. J. Cancer 45:416-422(1990).
//
RX   PubMed=3335022;
RA   Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J.,
RA   Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.;
RT   "Feasibility of drug screening with panels of human tumor cell lines
RT   using a microculture tetrazolium assay.";
RL   Cancer Res. 48:589-601(1988).
//
RX   PubMed=3930572; DOI=10.1172/JCI112082;
RA   Pirker R., FitzGerald D.J.P., Hamilton T.C., Ozols R.F., Laird W.J.,
RA   Frankel A.E., Willingham M.C., Pastan I.;
RT   "Characterization of immunotoxins active against ovarian cancer cell
RT   lines.";
RL   J. Clin. Invest. 76:1261-1267(1985).
//
RX   PubMed=6372095; DOI=10.1126/science.6372095;
RA   Rogan A.M., Hamilton T.C., Young R.C., Klecker R.W. Jr., Ozols R.F.;
RT   "Reversal of adriamycin resistance by verapamil in human ovarian
RT   cancer.";
RL   Science 224:994-996(1984).
//
RX   PubMed=6385258;
RA   Hamilton T.C., Young R.C., Ozols R.F.;
RT   "Experimental model systems of ovarian cancer: applications to the
RT   design and evaluation of new treatment approaches.";
RL   Semin. Oncol. 11:285-298(1984).
//
RX   PubMed=7718330; DOI=10.1016/0959-8049(94)00472-H;
RA   Baguley B.C., Marshall E.S., Whittaker J.R., Dotchin M.C., Nixon J.,
RA   McCrystal M.R., Finlay G.J., Matthews J.H.L., Holdaway K.M.,
RA   van Zijl P.;
RT   "Resistance mechanisms determining the in vitro sensitivity to
RT   paclitaxel of tumour cells cultured from patients with ovarian
RT   cancer.";
RL   Eur. J. Cancer 31:230-237(1995).
//
RX   PubMed=9041185;
RA   Johnson S.W., Laub P.B., Beesley J.S., Ozols R.F., Hamilton T.C.;
RT   "Increased platinum-DNA damage tolerance is associated with cisplatin
RT   resistance and cross-resistance to various chemotherapeutic agents in
RT   unrelated human ovarian cancer cell lines.";
RL   Cancer Res. 57:850-856(1997).
//
RX   PubMed=10700174; DOI=10.1038/73432;
RA   Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T.,
RA   Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A.,
RA   Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N.,
RA   Botstein D., Brown P.O.;
RT   "Systematic variation in gene expression patterns in human cancer cell
RT   lines.";
RL   Nat. Genet. 24:227-235(2000).
//
RX   PubMed=12080474; DOI=10.1038/sj.onc.1205542;
RA   Manzano R.G., Montuenga L.M., Dayton M., Dent P., Kinoshita I.,
RA   Vicent S., Gardner G.J., Nguyen P., Choi Y.-H., Trepel J.,
RA   Auersperg N., Birrer M.J.;
RT   "CL100 expression is down-regulated in advanced epithelial ovarian
RT   cancer and its re-expression decreases its malignant potential.";
RL   Oncogene 21:4435-4447(2002).
//
RX   PubMed=12960427; DOI=10.1091/mbc.E03-05-0279;
RA   Schaner M.E., Ross D.T., Ciaravino G., Sorlie T., Troyanskaya O.G.,
RA   Diehn M., Wang Y.C., Duran G.E., Sikic T.L., Caldeira S., Skomedal H.,
RA   Tu I.-P., Hernandez-Boussard T., Johnson S.W., O'Dwyer P.J., Fero M.J.,
RA   Kristensen G.B., Borresen-Dale A.-L., Hastie T., Tibshirani R.,
RA   van de Rijn M., Teng N.N.H., Longacre T.A., Botstein D., Brown P.O.,
RA   Sikic B.I.;
RT   "Gene expression patterns in ovarian carcinomas.";
RL   Mol. Biol. Cell 14:4376-4386(2003).
//
RX   PubMed=15748285; DOI=10.1186/1479-5876-3-11;
RA   Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L.,
RA   Morse H.C. III, Stroncek D., Marincola F.M.;
RT   "HLA class I and II genotype of the NCI-60 cell lines.";
RL   J. Transl. Med. 3:11.1-11.8(2005).
//
RX   PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433;
RA   Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C.,
RA   O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L.,
RA   Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S.,
RA   Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C.,
RA   Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A.,
RA   Mironenko T., Parker A., Perry J., Raine K.M., Richardson D.,
RA   Shepherd R., Small A., Smith R., Solomon H., Stephens P.J.,
RA   Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.;
RT   "Mutation analysis of 24 known cancer genes in the NCI-60 cell line
RT   set.";
RL   Mol. Cancer Ther. 5:2606-2612(2006).
//
RX   PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921;
RA   Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y.,
RA   Chanock S.J., Weinstein J.N.;
RT   "DNA fingerprinting of the NCI-60 cell line panel.";
RL   Mol. Cancer Ther. 8:713-724(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22068913; DOI=10.1073/pnas.1111840108;
RA   Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J.,
RA   Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V.,
RA   Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R.,
RA   Ambudkar S.V., Gottesman M.M.;
RT   "Redefining the relevance of established cancer cell lines to the
RT   study of mechanisms of clinical anti-cancer drug resistance.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011).
//
RX   PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017;
RA   Kong D.-X., Yamori T.;
RT   "JFCR39, a panel of 39 human cancer cell lines, and its application in
RT   the discovery and development of anticancer drugs.";
RL   Bioorg. Med. Chem. 20:1947-1951(2012).
//
RX   PubMed=22347499; DOI=10.1371/journal.pone.0031628;
RA   Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.;
RT   "Mass homozygotes accumulation in the NCI-60 cancer cell lines as
RT   compared to HapMap trios, and relation to fragile site location.";
RL   PLoS ONE 7:E31628-E31628(2012).
//
RX   PubMed=22384151; DOI=10.1371/journal.pone.0032096;
RA   Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H.,
RA   Yoon C.N., Chang Y.-T.;
RT   "Identification of cancer cell-line origins using fluorescence
RT   image-based phenomic screening.";
RL   PLoS ONE 7:E32096-E32096(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22628656; DOI=10.1126/science.1218595;
RA   Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L.,
RA   Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.;
RT   "Metabolite profiling identifies a key role for glycine in rapid
RT   cancer cell proliferation.";
RL   Science 336:1040-1044(2012).
//
RX   PubMed=23839242; DOI=10.1038/ncomms3126;
RA   Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.;
RT   "Evaluating cell lines as tumour models by comparison of genomic
RT   profiles.";
RL   Nat. Commun. 4:2126.1-2126.10(2013).
//
RX   PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342;
RA   Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L.,
RA   Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L.,
RA   Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.;
RT   "The exomes of the NCI-60 panel: a genomic resource for cancer biology
RT   and systems pharmacology.";
RL   Cancer Res. 73:4372-4382(2013).
//
RX   PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018;
RA   Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C.,
RA   Wilhelm M., Kuster B.;
RT   "Global proteome analysis of the NCI-60 cell line panel.";
RL   Cell Rep. 4:609-620(2013).
//
RX   PubMed=24023729; DOI=10.1371/journal.pone.0072162;
RA   Anglesio M.S., Wiegand K.C., Melnyk N., Chow C., Salamanca C.M.,
RA   Prentice L.M., Senz J., Yang W., Spillman M.A., Cochrane D.R.,
RA   Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.;
RT   "Type-specific cell line models for type-specific ovarian cancer
RT   research.";
RL   PLoS ONE 8:E72162-E72162(2013).
//
RX   PubMed=24279929; DOI=10.1186/2049-3002-1-20;
RA   Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R.,
RA   Hirshfield K.M., Oltvai Z.N., Vazquez A.;
RT   "The metabolic demands of cancer cells are coupled to their size and
RT   protein synthesis rates.";
RL   Cancer Metab. 1:20.1-20.13(2013).
//
RX   PubMed=24670534; DOI=10.1371/journal.pone.0092047;
RA   Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.;
RT   "High resolution copy number variation data in the NCI-60 cancer cell
RT   lines from whole genome microarrays accessible through CellMiner.";
RL   PLoS ONE 9:E92047-E92047(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27235858; DOI=10.1016/j.ygyno.2016.05.028;
RA   Hernandez L., Kim M.K., Lyle L.T., Bunch K.P., House C.D., Ning F.,
RA   Noonan A.M., Annunziata C.M.;
RT   "Characterization of ovarian cancer cell lines as in vivo models for
RT   preclinical studies.";
RL   Gynecol. Oncol. 142:332-340(2016).
//
RX   PubMed=27377824; DOI=10.1038/sdata.2016.52;
RA   Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J.,
RA   Vandesompele J.;
RT   "Long non-coding RNA expression profiling in the NCI60 cancer cell
RT   line panel using high-throughput RT-qPCR.";
RL   Sci. Data 3:160052-160052(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27807467; DOI=10.1186/s13100-016-0078-4;
RA   Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J.,
RA   Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.;
RT   "A map of mobile DNA insertions in the NCI-60 human cancer cell
RT   panel.";
RL   Mob. DNA 7:20.1-20.11(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=32612269; DOI=10.1038/s41598-020-67533-1;
RA   De Haven Brandon A., Box G., Hallsworth A., Court W., Matthews N.,
RA   Herodek B., Arteagabeitia A.B., Valenti M., Kirkin V.;
RT   "Identification of ovarian high-grade serous carcinoma cell lines that
RT   show estrogen-sensitive growth as xenografts in immunocompromised
RT   mice.";
RL   Sci. Rep. 10:10799-10799(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//